Washington, D.C. 20549

 Form 6-K

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

For the month of November 2018

Commission File Number 001-37626

Mesoblast Limited

(Exact name of Registrant as specified in its charter)

Not Applicable

(Translation of Registrant’s name into English)

Australia
(Jurisdiction of incorporation or organization)

 

Silviu Itescu

Chief Executive Officer and Executive Director

Level 38

55 Collins Street

Melbourne 3000

Australia

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:

Form 20-F ☑ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes ☐ No ☑

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes ☐ No ☑

 

---

INFORMATION CONTAINED ON THIS REPORT ON FORM 6-K

On November 30, 2018, Mesoblast Limited filed with the Australian Securities Exchange the Chairman’s Annual General Meeting address, presentation to Annual General Meeting and results of Annual General Meeting, which are attached hereto as Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3, and are incorporated herein by reference.

 

 

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized.

Dated: December 4, 2018

---

INDEX TO EXHIBITS

 

 

Exhibit 99.1

 

 

Chairman’s Address to the Mesoblast 2018 Annual General Meeting

 

Welcome to the Mesoblast 2018 Annual General Meeting.

 

There has been substantial progress made this year, with a number of key clinical and commercial highlights.

 

Specifically, our graft versus host disease product candidate successfully completed its Phase 3 trial and is on a runway for Biologics License Application filing and, if successful commercial launch.

 

Our heart failure product candidate successfully achieved a clinically meaningful outcome in a Phase 2 trial in end-stage heart failure patients with left ventricular assist devices, and we expect to have fulsome FDA discussions shortly on the regulatory approval pathway.

 

Also this year, we entered into a strategic partnership with China’s premier cardiovascular company, Tasly Pharmaceutical Group.

 

We have maintained tight expenditure across the Company whilst at the same time boosting our balance sheet. Cash reserves during the year were augmented by an upfront fee from Tasly. Additional funds have been received and are available under arrangements established this year with Hercules Capital and NovaQuest Capital Management.

 

During the year, two United States-based non-executive Directors with extensive pharmaceutical and commercial expertise joined the Board of Directors. The Company will leverage the skillsets of Shawn Cline Tomasello and Joe Swedish to provide valuable guidance on commercial launch and reimbursement activities at this important junction in the Company’s evolution. We thank Dr Ben-Zion Weiner, who retired as Director during the year, for his significant contributions over the past five years. As part of the process of moving towards a United States-centric commercial organization, I will be retiring from the Board at the end of March 2019 after completing the installation of a new Chairman of your Company. This will facilitate a structured and progressive succession plan as we move into the commercialization phase.

 

We would like to thank all of our shareholders for your ongoing support and belief in the tremendous potential of our cell therapies. We remain absolutely focused on delivering shareholder value.

 

Mesoblast enters 2019 with one product candidate with near-term commercial potential, a second having achieved clinical outcomes in line with FDA guidance for an approvable pathway, and two additional Phase 3 assets also for indications with significant, unmet medical needs.  

 

I would now like to ask our Chief Executive Silviu Itescu to provide a detailed insight into our corporate strategy.

Thank you.

 

 

Brian Jamieson                                                                                        November 30, 2018

 

 

 

 

 

 

 

 

 

 

---

 

Forward-Looking Statements

This announcement includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about the timing, progress and results of Mesoblast’s preclinical and clinical studies; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies; the timing or likelihood of regulatory filings and approvals; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

 

 

For further information, please contact:

 

Schond Greenway

Investor Relations

T: +1 212 880 2060

E: schond.greenway@mesoblast.com 

 

 

Julie Meldrum

Corporate Communications

T: +61 3 9639 6036

E: julie.meldrum@mesoblast.com

 

 

 

 

November 30, 2018 Nasdaq: MESO ASX: MSB 2018 Annual General Meeting Dr Silviu Itescu, Chief Executive Exhibit 99.2

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this presentation are forward-looking statements. Words such as, but not limited to, “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “targets,” “likely,” “will,” “would,” “could,” and similar expressions or phrases identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and future events , recent changes in regulatory laws, and financial trends that we believe may affect our financial condition, results of operation, business strategy and financial needs. These statements may relate to, but are not limited to: expectations regarding the safety or efficacy of, or potential applications for, Mesoblast's adult stem cell technologies; expectations regarding the strength of Mesoblast's intellectual property, the timeline for Mesoblast's regulatory approval process, and the scalability and efficiency of manufacturing processes; expectations about Mesoblast's ability to grow its business and statements regarding its relationships with current and potential future business partners and future benefits of those relationships; statements concerning Mesoblast's share price or potential market capitalization; and statements concerning Mesoblast's capital requirements and ability to raise future capital, among others. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. You should read this presentation together with our financial statements and the notes related thereto, as well as the risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast's actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, include, without limitation: risks inherent in the development and commercialization of potential products; uncertainty of clinical trial results or regulatory approvals or clearances; government regulation; the need for future capital; dependence upon collaborators; and protection of our intellectual property rights, among others. Accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise. | 2

Our Mission Mesoblast is committed to bring to market disruptive cellular medicines to treat serious and life-threatening illnesses |

Premier Global Cellular Medicines Company Late Stage Pipeline Commercialization Disruptive Technology Platform1 Disruptive technology which targets the most severe disease states refractory to conventional therapies Well characterized multimodal mechanisms of action Underpinned by extensive, global IP estate First approved products commercialized by licensees in Japan2 and Europe3 Increasing revenues and milestone payments Industrial-scale manufacturing to meet commercial demand Building focused U.S. sales force for upcoming GVHD product launch 2 blockbuster product candidates in heart failure and back pain Phase 3 trials Upcoming FDA interactions under RMAT regarding Phase 2 LVAD trial results China cardiovascular partnership in place Global partnership discussions to leverage commercial capabilities Mesenchymal precursor cells (MPCs) and their culture-expanded progeny mesenchymal stem cells (MSCs). Licensee JCR Pharmaceuticals Co., Ltd. received the first full PMDA approval for an allogeneic cellular medicine in Japan and markets this product under its trademark, TEMCELL® Hs Inj. Licensee Takeda received first central marketing authorization approval from the European Commission for an allogeneic stem cell therapy and markets this product under its trademark, Alofisel®.

IN DEVELOPMENT PLATFORM PRODUCT THERAPEUTIC AREA APPROVAL COMMERCIAL RIGHTS MSC (Bone Marrow) TEMCELL® HS Inj1 Acute Graft Versus Host Disease Japan MSC (Adipose) Alofisel®2 Perianal Fistula Global MARKETED Multiple Commercial Opportunities Mesoblast receives royalty income from its licensee JCR Pharmaceuticals Co Ltd on sales of JCR’s TEMCELL® Hs. Inj. product in Japan Mesoblast will receive royalty income from its licensee Takeda Pharmaceuticals on Takeda’s worldwide sales of its product Alofisel® in the local treatment of perianal fistulae Study funded by the United States National Institutes of Health (NIH) and the Canadian Health Research Institute; conducted by the NIH-funded Cardiothoracic Surgical Trials Network Tasly's rights are limited to China; Tasly also has rights to develop MPC-25-IC for AMI This chart is figurative and does not purport to show individual trial progress within a clinical program PLATFORM PRODUCT CANDIDATE THERAPEUTIC AREA PRE-CLINICAL PHASE 2 PHASE 3 COMMERCIAL RIGHTS MSC Remestemcel-L Acute Graft Versus Host Disease MPC Revascor Advanced HF (Class II/III) End-Stage HF (Class III/IV)3 China4 MPC MPC-06-ID Chronic Low Back Pain MPC MPC-300-IV Rheumatoid Arthritis Diabetic Nephropathy Includes remestemcel-L (Crohn’s disease – biologic refractory), MPC-25-IC (Acute Cardiac Ischemia), MPC-25-Osteo (Spinal Fusion) and MPC-75-IA (Knee Osteoarthritis) TIER 1 TIER 2 1st allogeneic regen med approved in Japan 1st allogeneic regen med approved in Europe

Partnerships and License Agreements | Exclusive cardiovascular rights in China Mesoblast received US$40 million on closing, eligible to receive additional milestones and royalties Tasly expects to meet with China’s regulatory authority in early 2019 to discuss a pathway for approval of Mesoblast heart failure cell therapy in China Patent license agreement entered in Dec 2017 with Takeda (formerly TiGenix NV) providing exclusive access to certain IP for local treatment of perianal fistulae Mesoblast is eligible to receive €20 million in milestone payments plus royalties upon commercial sales of Alofisel ® worldwide JCR has rights to use our MSC technology to treat acute GVHD in Japan Its product, TEMCELL ® HS Inj., was the first fully approved allogeneic cellular medicine in Japan Royalties and milestones received in last twelve months exceed US$5 million License expanded in Oct 2018 to cover use in treatment of epidermolysis bullosa – a highly debilitating and sometimes lethal skin disease

~800 Patents and patent applications (69 Patent families) across all major jurisdictions Covers composition of matter, manufacturing, and therapeutic applications of mesenchymal lineage cells Enables licensing to third parties for different indications, when in alignment with our corporate strategy, e.g.TiGenix (subsequently acquired by Takeda) Provides strong global protection against competitors seeking to develop products in areas of core commercial focus Mesenchymal Lineage Precursors and Progeny Global IP Estate Provides Substantial Competitive Advantage Markets U.S. , Europe, China, and Japan Sources Allogeneic, Autologous, (Bone Marrow, Adipose, Dental Pulp, Placenta), Pluripotent (iPS) Diseases All Tier 1 & Tier 2 Indications, and multiple additional conditions

Commercial-Scale Manufacturing Capability Immune privileged nature of mesenchymal lineage cells enables allogeneic “off the shelf” product candidates Culture expansion scalable to produce anticipated commercial quantities Management know-how in regulatory activities necessary for product approval and commercial launch | Lonza contract manufacturing facility in Singapore We believe remestemcel-L will be the first commercially produced allogeneic mesenchymal lineage cell product registered for sale in the U.S.

Board of Directors – Structured Succession Plan to Bring Complementary Skills: Proven FDA product approval capabilities Commercial launch expertise Reimbursement and health system expertise Extensive global transactional record Management – Expand Know-How to Support Commercial Launch Plans: Commercial leadership with proven track record to roll out launch team Operational leadership to drive product life cycle management, commercial manufacturing and regulatory interactions Commercial Organizational Transition

Remestemcel-L: Graft Versus Host Disease Pathway to Market TEMCELL® HS Inj. sales experience in Japan informs commercial strategy for the U.S. Phase 3 successfully completed Fast Track designation provides eligibility for FDA priority review Commercialization strategy in place for product launch Building out efficient, targeted sales force $700m US/EU addressable market, no competing approved products FDA Biologic License Application filing planned Q1 2019

Source: Simon-Kucher & Partners 2017. Primary research 2017; Payers n=35, KOLs n=15, Cath lab managers n=4. Corlanor® (ivabradine) approved by FDA (April 2015). ENTRESTO® (sacubitril/valsartan) approved by FDA (July 2015). GlobalData-PharmaPoint Heart Failure (2016); McMurray et al., 2012;Yancy et al., 2013, 2016 ACC/AHAHFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. Early ACEI or ARB Statins Beta blockers Re-vascularization or valvular surgery Advanced End-Stage Pharmacological Add-on Diuretics for fluid retention Aldosterone antagonists Hydralazine / isosorbide dinitrate Digitalis New Oral Therapies for Class II-IV2 If ACEI / ARB tolerated, sacubitril/valsartan Heart Failure Disease Progression Class I Class IV Common Treatment Pathway in Progressive Heart Failure1 Revascor: Targeting Patients with Advanced Heart Failure Refractory to Standard of Care Mesoblast Target Market: Advanced and End-Stage HF patients3 Cardiac Resynchronization Therapy (CRT) Implantable Cardioverter-Defibrillator (ICD) LVAD Heart transplants Limited Therapeutic Options

Blood Vessel (Endothelial) Dysfunction in the Heart and Major Organs is at the Core of Progressive Heart Failure Mesoblast MPCs have been shown to reverse inflammation-related endothelial dysfunction1 1 Dooley et al. Effect of MPCs on the systemic inflammatory response and endothelial dysfunction in an ovine model of collagen-induced arthritis. PLOS One, May 7, 2015. MPC IL-1β TNFα Inflammation in HF `M1 M2 Neovascularization Cardiomyocyte Survival NFkB SDF-1 VEGF Ang1 Smooth muscle cells FGF2 PDGF IL-10 Endothelial cells TNFα IL-1�� IL-6 PGE2 M1

Right Ventricular Failure and Increased Pressure in GI Blood Vessels GI Blood Vessels are Abnormal in LVAD Patients Enlarged right atrium GI Bleeding in LVAD Patients due to Inflammation-Related Endothelial Dysfunction Source: 1.  Grosman-Rimon L, Jacobs I,  Tumiati LC, et al. Longitudinal assessment of inflammation in recipients of continuous-flow left ventricular assist devices. Can. J. Cardiol. 2015;31:348–356.  ​2.  Grosman-Rimon L, Billia F, Fuks A, et al. New therapy, new challenges: The effects of long-term continuous flow left ventricular assist device on inflammation. Int J Cardiol 2016;215:424-430. 3.  Itescu S, Schuster M, Burke E, et al.  Immunobiologic consequences of assist devices.  Cardiol Clin 2003;21:119–133. 4.  Klovaite J, Gustafsson F, Mortensen SA, et al.  Severely impaired von Willebrand factor-dependent platelet aggregation in patients with a continuous-flow left ventricular assist device (HeartMate II). J Am Coll Cardiol 2009;53:2162–2167. 5.  Joyce D, Crow S, Li Z, et al. Pilot investigation of a novel testing strategy for bleeding in ventricular assist device recipients. J Heart Lung Transplant 2012;31:750–756. Mesoblast MPCs significantly reduced GI bleeding in two randomized controlled clinical trials in LVAD patients

Plan to meet with FDA in H1 2019 to discuss potential approval pathway In end-stage heart failure patients with LVADs, inflammation-related endothelial dysfunction results in severe GI bleeding and recurrent hospitalizations Treatment of end-stage heart failure patients with our MPCs in two NIH funded studies showed a reduction in GI bleeding and related hospitalizations FDA guidance has indicated that GI bleeding associated with LVADs is a clinically meaningful outcome Mesoblast has received RMAT designation for use of Revascor as an adjunct to LVAD implantation, enabling eligibility for FDA priority review and accelerated approval > $500m (US only) addressable market Revascor: End-stage LVAD Heart Failure Program Pathway to Market

Revascor: Advanced Heart Failure New therapies needed to reduce hospitalizations and mortality Phase 3 trial in advanced heart failure has enrolled >90% of patients Majority of patients in this Phase 3 trial have ischemic heart failure Revascor significantly improved LVAD wean tolerance and reduced hospitalizations from GI bleeding in ischemic heart failure patients in NIH-funded Phase 2 trial MPC-06-ID: Back Pain Limited treatment options for patients who fail conservative therapy include opioids and surgery 50% of opioid prescriptions are for chronic low back pain Opioid crisis is associated with a high rate of overdose and accidental death Urgent need for novel therapies to avoid opioid use Phase 3 study completed enrollment ~400 patients in March 2018 Blockbuster Product Opportunities

Global Partnerships to Commercialize Blockbuster Assets Global pharma partnering discussions fueled by positive late-stage trial results, regulatory interactions and regional licenses Advanced discussions with multiple potential partners for global commercialization of cell therapies for: advanced heart failure chronic low back pain due to disc degeneration Partners will bring: access to high growth markets clinical, regulatory and manufacturing expertise established extensive commercial footprint

Significant Increase in Revenue Revenue for the quarter ending September 30, 2018 (US$m) For the quarter ending September 30, 2018 September 30, 2017 $ Change % Change Milestone revenue 10.5 0.5 10.0 NM Commercialization revenue 1.0 0.6 0.4 66% Interest revenue 0.2 0.1 0.1 93% Total revenue 11.6 1.2 10.5 NM First quarter FY2019 revenue increased by US$10.5 million vs 2018 revenue due to: Commercialization revenue from royalty income on sales of TEMCELL®1 HS. Inj. increased 66% for the quarter and 116%2 for the 12 months ended September 30, 2018 compared to the 12 months ended September 30, 2017 US$10 million of milestone revenue in relation to establishing a strategic cardiovascular partnership with Tasly in China TEMCELL® HS Inj. is a registered trademark of JCR Pharmaceuticals Co. Ltd. Growth reported in constant currency which eliminates the effects of fluctuations in foreign exchange rates between different reporting periods.

Cash Position Strengthened through Strategic Transactions Balance sheet cash (US$m) Pro forma cash on hand at September 30 includes US$40 million received in October 2018 on closing of the strategic cardiovascular partnership with Tasly previously announced in July 2018 An additional US$50 million may be available under existing arrangements with Hercules Capital and NovaQuest, subject to achievement of certain milestones September 30, 2018 June 30, 2018 $Change Reported cash on hand 55.1 37.8 17.3 NovaQuest financing agreement - 39.0 (39.0) Tasly strategic partnership 40.0 40.0 - Pro forma cash on hand 95.1 116.8 (21.7)

Corporate Milestones Remestemcel-L for Acute Graft Versus Host Disease Successfully met all efficacy and safety endpoints through six months FDA meetings and BLA filing (Q4 CY18 – Q1 CY19) Revascor for Advanced and End-Stage Heart Failure Meet with FDA to discuss the recent LVAD phase 2b study results for the clinically meaningful GI bleeding data (1H CY19) Phase 3 events-driven trial in advanced heart failure enrollment completion (Q4 CY18 – Q1 CY19) MPC-06-ID for Chronic Low Back Pain Phase 3 trial completed enrollment (Q1 CY18) Completed non-dilutive transactions for commercialization of MSC-100-IV (remestemcel-L) Establish regional strategic and commercial licensing arrangements (China, Japan, Europe) Establish global commercial partnerships; in advanced discussions on blockbuster products

Questions? |

November 30, 2018 Nasdaq: MESO ASX: MSB Commercial Launch Plans Eric Strati Pharm.D., MBA

Mesoblast is Committed to Patient Access and Maximizing Value for all Key Stakeholders Mesoblast Culture Highly driven and passionate organization focused on improving the lives of those suffering from life threatening diseases Experienced Commercial Team High commercial acumen underpinned by strong scientific foundation and knowledge of reimbursement dynamics within health systems / transplant centers Targeted Commercial Objectives Optimize patient access while realizing the full value of Mesoblast products Provide effective product education and distribution support

Mesoblast Planned Commercial Launch Activities for Lead Products Targeted for > $1bn Market Combined1,2,3 US aGVHD Pediatric Launch US End-Stage HF Launch Build targeted highly effective field team Pre-launch engagement with payers and complete hospital account profiling Finalize distribution pathway and price for remestemcel-L Right size expansion of field team to support targeted US LVAD launch preparation Ongoing payer and health system engagement aGVHD High-Risk Adult Launch EU aGVHD Pediatric Launch 1 Sources for GVHD Market Assessment: CIBMTR Current Uses and Outcomes of Hematopoietic Cell Transplantation 2017 Summary., Passweg JR, Baldomero, H (2016) Hematopoietic Stem Cell Transplantation in Europe 2014., Data on file, 2 Sources for LVAD Market Assessment: Agency for Healthcare Research and Quality – Healthcare Cost and Utilization Project-https://www.ahrq.gov/data/hcup/index.html – ICD-9 37.6., Data on file, 3 Subject to FDA discussions under existing RMAT designation Leverage EU distributor for aGVHD launch Near-Term Mid-Term Long-Term

Remestemcel-L: US Launch Strategy to Maximize Patient Access with Limited Investment Pre-Launch Activities Engage with key payers pre-launch to solidify market access and pricing strategy; support with appropriate health care economic information Pricing and Reimbursement driven by cost savings from reduction in length of hospital stay and improved survival1,2,3 Launch Activities Target top 15 centers which represent ~50% of patient volume4 Support access through patient centric program 1, 2016 claims analysis with Anthem/HealthCore – Data on File, 2 Data on file, 3 Mesoblast remestemcel-L study 001 trial results 4 GVHD Market Assessment: CIBMTR Current Uses and Outcomes of Hematopoietic Cell Transplantation 2017 Summary

0 7 6 Reaction to Tested Target Profile2 Max Rating Product Attributes 1 ZS Associates June 2018 Qualitative Market Research: MCO Medical Directors n=5, Transplant Center Directors n= 5, Hospital Pharmacy Directors n=5, AMC-based Hem/Oncs / KOLs n=3 2 Tested Target Profile reflective of Mesoblast phase III study 001 results Results from Providers/Payers Qualitative US Market Research1 Most Significant Value Drivers for Remestemcel-L Day 100 Survival rate Day 28 overall response rate No increase in infections Largest clinical data set (n ~300) Ability to administer the drug outpatient Median Response (n=20) “Remestemcel-L is Expected to Become Standard of Care” - Multiple Respondents1

Revascor: Adjunct Therapy to LVAD Indication Commercial Strategy will Leverage Commercial Infrastructure Pre-Launch Activities Engage with key payers pre-launch to develop and solidify market access and pricing strategy Pricing and Reimbursement driven by cost savings from reduced GI-bleed hospitalizations and associated co-morbidities Apply for New Technology Add-on Payment (NTAP) program under which Centers for Medicare and Medicaid Services provides additional payments for qualified new technologies provided in the inpatient setting. Launch Activities Primarily target top 40 centers at launch representing ~75% of patient volume1 ~20% overlap with Tier 1 target transplant centers for aGVHD2 1 Medicare provider inpatient charge data-FY2016 - https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-Charge-Data/Inpatient2016.html 2 https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/newtech.html

Questions? |

Exhibit 99.3

 

 

30 November 2018

 

 

 

 

 

 

 

Mesoblast Limited (MSB)

Results of Annual General Meeting Held 30 November 2018

 

 

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001, we advise details of the resolutions and the proxies received in respect of each resolution as per the attached report.

 

 

 

Yours faithfully

Charlie Harrison
Company Secretary

 

 

 

---

Exhibit 99.3

 

 

 

 

---

Exhibit 99.3